Placebo Reduces Fatigue in Cancer Survivors

Cancer-related fatigue is a debilitating adverse effect that can disrupt a patient’s life and have a lasting impact even after the end of treatment. Effective treatments to alleviate fatigue could result in unwanted conditions, such as psychosis, panic, or heart failure.

Placebo pills may be an effective method for cancer survivors who are struggling to manage fatigue according to a study published by Nature Scientific Reports. Patients even noticed relief when they were made aware the treatment was a placebo, the study found.

Patients were explicitly told the pill was a placebo and had a clear understanding when enrolling in the study. Researchers found that the patients’ opinion of the placebo effect did not affect whether they experienced improved fatigue.

"Some people who thought the placebo wouldn't do anything had a good response; others who believed it would help didn't have a response," said lead author Teri Hoenemeyer, PhD. "Fooling or deceiving patients may be unnecessary for placebo effects to produce benefits, with automatic neurological processes being a possible mechanism for the effects. This has revolutionary implications for how we might exploit the power of placebo effects in clinical practice."

The pills were made of cellulose and contained no active ingredients, according to the authors.

The study included 74 survivors of different types of cancer who experienced moderate-to-severe fatigue. Patients were randomized to receive placebo or the standard therapy for fatigue.

Patients randomized to receive the placebo were aware of the inactive treatment and were instructed to take 2 pills twice daily for 3 weeks.

After the initial 3 weeks, patients who received the usual treatment were given the option to switch to the placebo. Those who originally took the placebo discontinued treatment.

Patients knowingly taking the placebo experienced a significant improvement in fatigue and those who discontinued the placebo maintained their improvement, according to the study.

"Participants still had benefits three weeks after they stopped taking the placebo pills, which hasn't been shown before," said co-author Kevin Fontaine, PhD. "The extension of benefits even when the placebo pills are discontinued has been a surprise finding that has many placebo researchers excited."

Patients taking placebos reported a 29% reduction in fatigue severity and a 39% improvement in overall quality of life measures related to fatigue, according to the study.

The authors noted that open-label placebo pills have been shown to relieve symptoms in patients with irritable bowel syndrome, chronic low-back pain, and migraine headaches. These results suggest the treatment approach may also improve fatigue among cancer survivors.

"Cancer survivors report that fatigue is their most distressing symptom, even more distressing than other symptoms like nausea or pain, and clinicians struggle to find ways to help them with it," Dr Hoenemeyer said. "The effects of the placebo pills on fatigue were so dramatic that we had a number of the study patients ask if they could be given more placebo pills. For ethical reasons, we were unable to do so."

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Related Articles

Study findings suggest that triple-negative breast cancer incidence among black women is not generalizable to all women of African descent.
Slow walking speed associated with higher risk of poor outcomes for older patients with blood cancers.
An unhealthy microbiome caused by chronic antibiotic treatment could result in long-term inflammation within the tissue and tumor environment.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.